Literature DB >> 8499629

BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.

A Bedi1, B A Zehnbauer, M I Collector, J P Barber, M S Zicha, S J Sharkis, R J Jones.   

Abstract

Chronic myeloid leukemia (CML) is characterized by an initial chronic phase of expanded yet orderly clonal hematopoiesis that is distinguished by the BCR-ABL gene rearrangement. We found that although the mature myeloid compartment in patients with CML was expanded and entirely derived from the dominant leukemic clone, the primitive hematopoietic progenitor compartment did not show a corresponding expansion and was substantially enriched for cells without the BCR-ABL gene rearrangement. More importantly, primitive progenitors exhibiting the BCR-ABL gene rearrangement did not express either the BCR-ABL hybrid mRNA or fusion protein (P210). Expression of P210 protein and BCR-ABL mRNA increased with myeloid commitment in vivo as well as with growth factor-induced proliferation and differentiation of the primitive CML progenitors in vitro. This differential expression of BCR-ABL between primitive and mature CML progenitors may explain the expansion of the leukemic clone at the level of mature myeloid progenitors and granulocytes without a concomitant expansion of primitive CML progenitors. Because BCR-ABL mRNA is minimally expressed or may be absent in primitive CML progenitors, these cells may escape detection by reverse transcriptase-polymerase chain reaction and eradication by antisense oligonucleotides targeted against BCR-ABL mRNA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499629

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

Review 2.  The paradox of response and survival in cancer therapeutics.

Authors:  Carol Ann Huff; William Matsui; B Douglas Smith; Richard J Jones
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 3.  Cancer stem cells: relevance to clinical transplantation.

Authors:  Gabriel Ghiaur; Jonathan M Gerber; William Matsui; Richard J Jones
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

4.  Controversies in cancer stem cells.

Authors:  Richard J Jones
Journal:  J Mol Med (Berl)       Date:  2009-10-23       Impact factor: 4.599

5.  A case report of a 33-year chronic phase survivor of chronic myeloid leukemia.

Authors:  Ou Ji; Qun Shen; Ya-Cheng Zhang; Jian-Min Ji; Guang-Rong Zhu; Lin Lin; Xiang-Tu Kong; Wen Xia; Peng-Jun Jiang
Journal:  Med Oncol       Date:  2011-02-27       Impact factor: 3.064

Review 6.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

Review 7.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

Review 8.  Urothelial carcinoma: stem cells on the edge.

Authors:  William D Brandt; William Matsui; Jonathan E Rosenberg; Xiaobing He; Shizhang Ling; Edward M Schaeffer; David M Berman
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

9.  Cancer Stem Cells: From Bench to Bedside.

Authors:  Richard J Jones; William Matsui
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

Review 10.  Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.

Authors:  Takumi Era
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.